IRVINE, Calif., March 25, 2024 (Globe Newswire) — Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the registration of 12 pharmaceutical companies.th On March 23, 2024, the company became a participant in the company’s ongoing Phase 2 BESTOW study, which is directly evaluating tegopulvert and tacrolimus for the prevention of rejection in kidney transplants.
“We are pleased with the strong pace of enrollment in the Phase 2 BESTOW trial, which speaks to the fundamental demand for new immunosuppressive therapies for the tens of thousands of patients undergoing kidney transplants each year. I believe there is,” said David Alexandre C. Gross, MD, Chief Executive Officer.
Risk of organ failure in transplantation
In transplant procedures, organ rejection is a major cause of graft failure and can be life-threatening. Rejection occurs through allogeneic recognition, in which the recipient’s immune system identifies the transplanted organ as foreign tissue and triggers an immune response against the transplanted organ. To reduce the risk of rejection, patients receive lifelong immunosuppressive therapy. Calcineurin inhibitors (“CNIs”) are an important component of most immunosuppressive therapies to prevent acute and long-term organ transplant rejection. However, chronic exposure to CNIs (of which tacrolimus is the most commonly used drug) can lead to nephrotoxicity, hypertension, new onset diabetes due to pancreatic beta-cell toxicity, and even central nervous system side effects such as tremor. It is related to Regarding kidney transplants, 30-50% of kidney transplants fail in his 10-15 years of transplantation due to toxicity associated with CNI. Strategies to better and safely protect transplanted organs and extend their functional life represent important areas of unmet need in organ transplantation.
About Eledon Pharmaceuticals and Tegopulvert
Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing immunomodulatory therapies for the management and treatment of life-threatening conditions. The company’s lead investigational product is tegopulvert, an anti-CD40L antibody with high affinity for the CD40 ligand, a well-validated biological target with broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for immunomodulatory therapeutic interventions that do not deplete lymphocytes. Masu. Building on our deep historical knowledge of anti-CD40 ligand biology, we conduct preclinical and clinical research in renal allografts, xenografts, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. Please visit our website for more information. www.eledon.com.
Follow Eledon Pharmaceuticals on social media: linkedin; twitter
Forward-looking statements
This press release contains forward-looking statements that involve significant risks and uncertainties. Statements regarding the demand for new and better immunosuppressive therapies for patients undergoing kidney transplants, or regarding our other future expectations, plans, or prospects; Other descriptions that include the word “is there”. “”, “expect”, “estimate”, “intend”, “predict”, “plan”, “target”, “forward-looking”, “could”, “might” “No” and similar expressions constitute forward-looking statements in these Terms. Implications of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently uncertain and are subject to a number of risks and uncertainties, including: risks related to the safety and effectiveness of our drug candidates; risks related to clinical development schedules, including regulatory and clinical interactions and patient enrollment; risks related to the cost of clinical trials and the sufficiency of the Company’s capital resources to fund planned clinical trials; risks associated with the effects of the ongoing coronavirus pandemic; Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors. These risks and uncertainties and other risks and uncertainties that could cause the Company’s actual results to differ materially from the forward-looking statements contained herein include the Company’s Quarterly 10-Q , annual 10-K, and other filings. U.S. Securities and Exchange Commission (available at the following site) www.sec.gov. The forward-looking statements contained in this press release speak only as of the date of this press release and do not speak to future dates. The Company expressly disclaims any intention to update any forward-looking statements, whether as a result of or as a result of new information, future events. Otherwise.
Investor contact information:
stephen jasper
gilmartin group
(858) 525 2047
[email protected]
Media contact:
jenna urban
Berry & Company Public Relations Department
(212) 253 8881
[email protected]
Source: Eledon Pharmaceuticals
